hepat
b
viru
hbv
dna
viru
belong
hepadnavirida
famili
includ
hepatotrop
virus
hbv
virion
consist
extern
lipoprotein
envelop
intern
protein
nucleocapsid
icosahedr
symmetri
contain
viral
genom
dna
polymeras
hbv
genom
partial
doublestrand
circular
dna
molecul
four
partial
overlap
open
read
frame
encod
structur
nonstructur
viral
protein
core
antigen
hbcag
repres
structur
compon
viral
capsid
e
antigen
hbeag
nonstructur
protein
secret
serum
infect
host
larg
medium
small
envelop
glycoprotein
contain
hb
antigen
reactiv
dna
polymeras
revers
transcriptas
ribonucleas
function
hbv
x
antigen
hbx
express
transcript
regulatori
properti
follow
hepatocyt
infect
nucleocapsid
transport
nucleu
viral
dna
convert
coval
close
circular
dna
cccdna
form
minichromosom
act
templat
synthesi
genom
subgenom
transcript
importantli
cccdna
repres
reservoir
viru
persist
hepatocyt
nucleu
hbv
dna
fragment
integr
host
genom
event
although
necessari
viru
replic
promot
carcinogenesi
hepat
b
viru
infect
consid
world
health
organ
major
public
health
burden
high
rate
death
clinic
sequela
despit
avail
prophylact
vaccin
estim
million
peopl
worldwid
chronic
infect
hepat
b
viru
risk
develop
liver
cirrhosi
hepatocellular
carcinoma
chronic
hbv
infect
result
wide
rang
clinic
condit
associ
variabl
degre
hbv
control
rang
chronic
virem
patient
carri
huge
quantiti
antigen
blood
liver
immun
subject
occult
persist
trace
amount
viru
within
liver
without
detect
antigenemia
specif
five
phase
identifi
natur
histori
basi
patient
serolog
profil
liver
inflamm
hbeagposit
chronic
infect
previous
refer
immun
toler
phase
ii
hbeagposit
chronic
hepat
iii
hbeagneg
chronic
hepat
previous
refer
collect
immun
activ
phase
iv
hbeagneg
chronic
infect
previous
refer
inact
carrier
v
hbsagneg
occult
hbv
infect
antibodi
hbcag
antihbc
without
detect
antibodi
hbsag
antihb
case
immunosuppress
lead
hbv
reactiv
present
treatment
chronic
hbv
infect
chb
mainli
base
third
gener
nucleo
ide
analogu
nuc
therapi
target
revers
transcriptas
activ
hbv
polymeras
without
signific
occurr
viral
resist
nuc
oral
administ
well
toler
effect
suppress
hbv
replic
induc
biochem
histolog
improv
allow
partial
restor
virusspecif
cell
respons
loss
hbsag
observ
less
patient
five
year
therapi
thu
often
requir
longterm
administr
avoid
viru
reactiv
therapi
discontinu
due
persist
cccdna
nucleu
infect
hepatocyt
affect
significantli
nuc
therapi
altern
therapeut
option
base
interferonalpha
ifn
hbv
cure
achiev
ifntreat
patient
therapi
frequent
associ
sever
side
effect
therefor
clinic
need
safe
novel
treatment
shorten
durat
nuc
therapi
acceler
viru
control
enhanc
effect
current
antivir
therapi
hbvspecif
cell
chronic
hepat
b
scarc
function
defect
exhaust
state
key
determin
viru
persist
typic
hbv
specif
lymphocyt
deepli
dysfunct
untreat
chronic
patient
subject
abl
control
hbv
infect
spontan
follow
acut
infect
display
vigor
broad
antigenspecif
cell
respons
cell
impair
describ
anim
model
chronic
viru
infect
character
progress
hierarch
loss
antivir
cell
function
rang
function
inhibit
physic
delet
depend
upon
quantiti
antigen
peptid
durat
cell
exposur
high
antigen
load
featur
exhaust
virusspecif
cell
repres
upregul
multipl
coinhibitori
receptor
transcript
metabol
epigenet
defect
lack
protect
cell
memori
gener
addit
inhibitori
mechan
contribut
cell
dysfunct
chronic
hepat
b
compris
nutrient
deplet
hepat
microenviron
expans
neg
regulatori
nk
myeloidderiv
suppressor
cell
gmdsc
effect
suppress
cytokin
moreov
differ
subset
virusspecif
cell
differ
level
exhaust
coexist
chronic
infect
host
suggest
overal
exhaust
cell
popul
heterogen
term
phenotyp
function
transcript
profil
capac
express
antivir
function
base
line
evid
correct
antivir
cell
defect
boost
virusspecif
tcell
respons
cell
reacquir
capac
respond
effici
antigen
stimul
repres
ration
strategi
cure
chronic
hbv
infect
patient
new
immunotherapeut
approach
chronic
hepat
b
current
clinic
develop
design
improv
rate
hbsag
loss
antihb
seroconvers
chb
subject
compar
current
achiev
nucleo
ide
analogu
alon
review
focu
current
knowledg
emerg
immunebas
therapeut
strategi
chronic
hepat
b
viru
infect
includ
immun
checkpoint
inhibit
metabol
cell
target
therapi
figur
therapeut
cell
vaccin
autolog
cell
engin
includ
chimer
antigen
receptor
car
tcrredirect
cell
figur
first
report
chronic
lymphocyt
choriomening
viru
lcmv
infect
upregul
coinhibitori
receptor
immun
checkpoint
wide
describ
common
hallmark
exhaust
cell
differ
chronic
infect
tumor
model
inde
gene
express
profil
function
cell
analysi
virusspecif
cell
chronic
lcmvinfect
mice
led
character
role
play
highli
coexpress
inhibitori
molecul
tigit
btla
promot
dysfunct
phenotyp
exhaust
antigenspecif
cell
later
evid
effici
antivir
function
exhaust
cell
could
reconstitut
blockad
inhibitori
pathway
promot
expect
immunotherapi
potenti
treatment
chronic
infect
cancer
howev
antibodi
interf
ligand
eg
monotherapi
combin
checkpoint
target
show
efficaci
cancer
treatment
clinic
trial
still
limit
field
chronic
viral
infect
hiv
infect
blockad
believ
facilit
viru
latenc
revers
cell
howev
far
studi
conduct
artsuppress
patient
singl
lowdos
administr
lead
hivspecif
cell
improv
proport
subject
without
effect
residu
viremia
detect
singlecopi
assay
sca
addit
patient
chronic
hepat
c
viru
hcv
infect
modest
antivir
effect
observ
singl
dose
treatment
set
chronic
hbv
infect
coinhibitori
molecul
express
role
cell
exhaust
object
mani
vitro
vivo
investig
document
also
context
upregul
multipl
checkpoint
circul
intrahepat
virusspecif
cell
maxim
express
liverinfiltr
lymphocyt
addit
overexpress
sever
checkpoint
ligand
circul
monocyt
b
cell
intrahepat
non
parenchym
cell
ligand
liver
resid
kupffer
cell
like
contribut
cell
exhaust
mainten
moreov
exhaust
hbvspecif
cell
also
appear
prone
apoptosi
shown
upregul
death
receptor
proapoptot
mediat
bim
interestingli
high
level
associ
antivir
dysfunct
also
hbvspecif
cell
recent
virusspecif
b
cell
chronic
hbv
patient
addit
recent
studi
report
coexpress
inhibitori
checkpoint
sever
molecul
transcript
factor
differentiationactivationsurviv
marker
eg
tbet
eom
allow
defin
distinct
cell
subset
variou
degre
termin
differenti
function
impair
specif
differ
viral
epitop
hbv
core
polymeras
phenotyp
heterogen
alreadi
demonstr
account
variabl
sensit
function
restor
intervent
model
cell
exhaust
expect
repres
rational
identif
reliabl
predictor
outcom
also
context
immun
therapi
chronic
hbv
infect
although
mani
vitro
studi
show
blockad
induc
improv
b
cell
arm
cellular
immun
effici
effect
intrahepat
peripher
compart
becom
evid
blockad
alon
suffici
complet
revers
immun
function
impair
chronic
hbv
infect
therefor
order
improv
efficaci
blockad
test
associ
regulatori
pathway
manipul
show
variabl
degre
cell
respons
restor
interestingli
synergist
effect
stimul
blockad
report
significantli
augment
ifngamma
produc
hbvspecif
cell
vitro
preclin
experi
woodchuck
model
chronic
hepat
viru
whv
infect
show
associ
blockad
nucleosid
analogu
treatment
therapeut
dna
vaccin
boost
virusspecif
immun
lead
suppress
viral
replic
antiwh
antibodi
seroconvers
two
three
test
anim
recent
studi
describ
improv
control
viremia
antigenemia
induc
three
natur
whvinfect
woodchuck
associ
nucleosid
analogu
treatment
durabl
antivir
effect
therapi
withdraw
two
singl
dose
nivolumab
phase
trial
far
perform
nuc
treat
viral
suppress
hbeag
neg
chronic
hbv
patient
reduct
hbsag
titer
detect
limit
proport
patient
total
persist
hbsag
loss
one
sever
advers
event
report
effect
observ
hbsag
declin
potenti
antivir
cell
respons
addit
therapeut
vaccin
contain
core
envelop
x
antigen
abl
stimul
cellmedi
hbvspecif
respons
given
wide
variabl
efficaci
checkpoint
inhibit
vitro
vivo
studi
complex
individu
respons
treatment
current
investig
aim
identifi
fraction
patient
could
like
benefit
immunotherapi
genet
epigenet
factor
contribut
variabl
individu
checkpoint
express
develop
cell
exhaust
state
recogn
regard
herit
de
novo
dna
methyl
program
affect
cell
function
persist
upon
blockad
possibl
resist
immun
modulatori
treatment
revers
exhaust
describ
mous
model
chronic
viru
infect
sinc
exhaust
cell
undergo
deepli
alter
transcript
regulatori
program
combin
epigenet
drug
fdaapprov
dna
demethyl
agent
immun
checkpoint
blockad
alreadi
test
demonstr
effect
improv
antitumor
immunotherapi
although
promis
clinic
use
immun
checkpoint
blockad
may
howev
limit
potenti
side
effect
may
particularli
relat
gener
immun
activ
induc
checkpoint
blockad
could
give
rise
autoimmun
event
well
increas
liver
inflamm
might
lead
sever
degre
unwant
consequ
includ
hepat
exacerb
report
hbsagposit
cancer
patient
moreov
recent
studi
perform
hbsagtransgen
tg
mice
upon
tigitinhibit
show
therapeut
hbsag
vaccin
induc
inflamm
hepatocellular
carcinoma
hcc
celldepend
manner
data
underscor
risk
intervent
affect
hepat
immun
toler
view
evid
recurr
immunemedi
liver
damag
contribut
develop
cirrhosi
hcc
cell
differenti
activ
function
well
memori
gener
requir
dynam
metabol
adapt
order
cope
differ
biosynthet
energet
cellular
demand
also
chang
nutrient
avail
due
cell
migrat
one
tissu
thu
becom
increasingli
clear
immun
cell
metabol
ultim
shape
immun
respons
mani
studi
far
devot
understand
interdepend
cell
metabol
function
order
identifi
metabol
modul
strategi
relev
therapeut
applic
differ
clinic
field
cell
exhaust
pathogenet
relev
exampl
mitochondri
manipul
influenc
cell
dynam
provid
effect
mitochondri
fusionpromot
drug
treatment
improv
cell
fit
function
adopt
transfer
antitumor
cell
mice
moreov
dysregul
metabol
describ
mous
model
lcmv
infect
earli
metabol
alter
preced
onset
sever
cell
dysfunct
suppress
glycolysi
mitochondri
respir
associ
signific
transcript
chang
virusspecif
cell
contain
abnorm
larg
depolar
mitochondria
subvert
ultrastructur
increas
ro
product
persist
also
advanc
stage
exhaust
enrich
termin
differenti
cell
subset
blockad
could
partial
reliev
metabol
alter
mostli
cell
line
previou
report
demonstr
influenc
inhibitori
receptor
signal
cell
metabol
overexpress
transcript
coactiv
revers
dysregul
mitochondri
phenotyp
significantli
increas
cell
polyfunction
approach
also
appli
rescu
exhaust
tumorinfiltr
lymphocyt
posit
effect
overexpress
glucos
uptak
glycolysi
mitochondri
dysregul
well
antitumor
function
similarli
describ
tumor
nutrient
competit
restrict
tumor
microenviron
well
inhibitori
effect
accumul
metabolit
repres
factor
respons
cell
dysfunct
also
infect
liver
amino
acid
deplet
caus
consumpt
number
infiltr
cell
describ
part
immunosuppress
environ
decreas
arginin
level
granulocyt
subset
myeloidderiv
suppressor
cell
gmdsc
produc
arginas
shown
one
way
depriv
cell
essenti
amino
acid
transient
acut
hbv
patient
persist
chronic
infect
individu
particularli
infect
phase
without
overt
immunopatholog
immunotoler
inact
patient
find
confirm
partial
cell
function
reconstitut
follow
vitro
arginin
replenish
inflam
hypox
hepat
environ
may
also
contribut
signific
upregul
observ
exhaust
hbvspecif
cell
describ
heavili
depend
glucos
uptak
glycolysi
energi
product
limit
capac
use
oxid
phosphoryl
comparison
function
cmvspecif
cell
lcmv
also
chronic
hbv
infect
virusspecif
cell
display
abnorm
larg
depolar
dysfunct
mitochondria
rescu
addit
cultur
medium
mitochondri
dysfunct
high
proport
depolar
mitochondria
excess
high
ro
level
also
support
chronic
hepat
b
genomewid
transcriptom
studi
virusspecif
cell
show
extens
downregul
gene
code
differ
mitochondri
compon
electron
transport
chain
etc
fatti
acid
amino
acid
metabol
heme
biosynthesi
among
report
downregul
gene
exhaust
hbvspecif
cell
code
mitochondri
membran
fusion
protein
mitochondri
enzym
costimulatori
receptor
could
repres
factor
affect
correct
cell
differenti
consider
demonstr
role
metabol
plastic
function
memori
cell
develop
context
mitochondriatarget
antioxid
neutral
excess
ro
product
result
high
vitro
respons
rate
shown
signific
improv
mitochondri
depolar
etc
protein
express
well
hbvspecif
cell
cytokin
product
viabil
peripher
also
intrahepat
level
consid
multifacet
role
play
mitochondria
number
cellular
process
ultim
impact
tcell
prolifer
effector
function
mitochondri
modul
consid
perspect
immunemodulatori
strategi
target
multipl
dysregul
cellular
process
altern
complementari
approach
checkpoint
blockad
order
restor
cell
function
respons
antigen
stimul
render
hbvspecif
cell
effici
respons
boost
vaccin
sinc
spontan
resolut
hbv
infect
accompani
immun
reconstitut
stimul
hbvspecif
b
tcell
immun
therapeut
vaccin
context
chronic
infect
repres
ration
approach
overcom
immun
toler
therapeut
vaccin
attract
field
research
nevertheless
differ
therapeut
vaccin
attempt
hepat
b
far
unsuccess
date
sever
formul
test
anim
model
human
differ
categori
immunogen
develop
includ
protein
peptidebas
dna
viral
vectorbas
vaccin
mani
differ
vaccin
therapi
chronic
hbv
infect
patient
alreadi
evalu
clinic
trial
tabl
discuss
sinc
adenovirus
emerg
provid
optim
stimul
cell
compart
strategi
design
exploit
properti
among
viral
vectorbas
vaccin
consist
nonrepl
adenoviru
vector
encod
uniqu
fusion
protein
compos
modifi
core
polymeras
select
domain
envelop
protein
inject
abl
induc
robust
cell
respons
exert
antivir
effect
hbvpersist
mice
current
evalu
phase
ib
studi
chronic
patient
inhibit
hbv
replic
induc
antivir
therapi
improv
therapeut
vaccin
efficaci
novel
approach
call
thervacb
base
modifi
vaccinia
viru
ankara
mva
vector
express
hbsag
hbcag
propos
shown
elicit
strong
polyclon
cell
respons
invers
correl
antigen
level
hbvtg
mice
strategi
current
preclin
evalu
design
twostep
approach
base
initi
protein
prime
hbvspecif
cell
respons
cell
help
antibodi
product
lower
hbsag
titer
follow
subsequ
boost
mva
vector
order
optim
effici
activ
expans
hbvspecif
cell
respons
among
candid
vaccin
belong
proteinbas
categori
consist
heatinactiv
recombin
sacchyaromyc
cervisia
yeast
express
hbsag
core
x
antigen
yeast
compon
shown
adjuv
properti
reduc
frequenc
inhibitori
activ
regulatori
cell
treg
test
phase
trial
viral
suppress
chb
patient
recent
chronic
patient
combin
tenofovir
studi
induc
clinic
signific
reduct
hbsag
although
could
effici
promot
virusspecif
tcell
respons
break
tcell
toler
virem
hbeagneg
patient
absenc
clinic
benefit
despit
strong
immun
modulatori
effect
probabl
due
weaker
cell
stimul
view
essenti
role
play
cell
induc
b
cell
neutral
antibodi
moreov
partial
restor
envelopespecif
cell
respons
observ
studi
could
repres
anoth
import
caus
vaccin
failur
reduc
hbsag
load
line
concept
envelopespecif
respons
associ
complet
control
infect
antihb
seroconvers
novel
proteinbas
vaccin
candid
incorpor
hbsag
hbcag
current
clinic
trial
theravax
combin
saponinbas
iscomatrix
adjuv
administ
intranas
rout
addit
innov
vaccin
approach
consist
yeastderiv
hbsag
human
antihb
immunoglobulin
complex
combin
alum
adjuv
hbsaghbig
gener
data
support
idea
therapeut
vaccin
base
ration
choic
antigen
appropri
adjuvantsvir
vector
abl
induc
multispecif
broadli
crossreact
hbvspecif
cell
respons
associ
restor
cell
reactiv
envelop
polymeras
core
antigen
choic
repres
crucial
point
immun
strategi
sinc
probabl
use
therapeut
vaccin
target
hbsag
may
optim
achiev
clinic
immunolog
success
moreov
role
adjuv
emerg
critic
compon
overcom
differ
mechan
cell
dysfunct
view
also
recent
evid
vaccineadjuv
system
may
util
induc
benefici
epigenet
modif
set
anticanc
treatment
among
new
vaccin
belong
peptidebas
categori
present
clinic
trial
heptcelltm
compos
nine
multiepitop
peptid
includ
cell
epitop
target
multipl
hbv
genotyp
consist
immunodomin
epitop
deriv
region
tetanu
toxoid
dnabas
vaccin
also
studi
current
clinic
trial
one
novel
candid
consist
plasmid
encod
hbsag
consensu
sequenc
hbcag
administ
without
human
dna
plasmid
anoth
new
gener
dna
vaccin
contain
plasmid
encod
hb
hbc
hbpol
vaccin
need
administ
vivo
electropor
interestingli
approach
report
enhanc
vaccin
antigen
express
immunogen
moreov
use
adjuv
rescu
antivir
function
exhaust
hbvspecif
cell
conclus
gener
consider
therapeut
vaccin
efficaci
outlin
first
ideal
approach
aim
achiev
function
restor
b
cell
respons
like
need
longterm
control
hbv
infect
furthermor
import
open
issu
also
optim
therapeut
vaccin
addit
immunemodul
checkpoint
inhibitor
metabol
modul
overcom
hbvspecif
immun
exhaust
final
lower
antigen
load
cell
boost
minim
risk
relat
hepat
flare
favor
function
cell
restor
well
accur
select
patient
could
like
respond
immun
modul
repres
two
crucial
aspect
consid
vaccin
design
strategi
respect
last
point
better
character
cell
exhaust
heterogen
help
identifi
patient
popul
preval
exhaust
cell
subset
better
respons
cell
revit
strategi
could
thu
benefit
substanti
immun
modulatori
intervent
extent
cell
exhaust
overcom
whether
achiev
function
restor
suffici
hbv
control
still
open
issu
need
better
address
set
cell
engin
technolog
aim
gener
vitro
function
effici
lymphocyt
redirect
specif
hbv
reinfus
chronic
infect
host
repres
altern
strategi
overcom
possibl
ineffici
immun
modulatori
therapi
stimul
impair
hbvspecif
cell
respons
figur
vast
major
genet
engin
cell
adopt
transfer
therapi
far
target
treat
malign
lymphoma
leukemia
neuroblastoma
recent
report
indic
adopt
cell
transfer
current
compris
tcrengin
chimer
ag
receptor
car
cell
potenti
treat
varieti
diseas
includ
multipl
sclerosi
inflammatori
intestin
diseas
autoimmun
diseas
moreov
last
year
research
also
consid
extend
cell
engin
therapi
viru
infect
cmv
hbv
hcv
sar
regard
clinic
evid
potenti
effect
immunemodulatori
strategi
design
strengthen
hbvspecif
tcell
respons
adopt
transfer
engin
antigenspecif
lymphocyt
base
observ
virusspecif
cell
administr
bone
marrow
transplant
subject
clear
hbv
infect
spontan
patient
chronic
hbv
infect
led
viru
control
similarli
liver
transplant
patient
resolv
hbv
infect
receiv
hbsag
posit
graft
result
viral
clearanc
thu
adopt
tcell
therapi
use
autolog
cell
genet
engin
express
canon
hla
class
restrict
tcr
chimer
antigen
receptor
car
target
hbv
hcv
chronic
viral
infect
attempt
hbv
infect
redirect
specif
exist
cell
transfer
hbvtcr
gene
far
tri
hbv
transgen
mice
patient
relaps
hbvrelat
hcc
briefli
circul
lymphocyt
isol
chb
patient
expand
activ
vitro
engin
use
viral
vector
encod
hbvspecif
tcr
redirect
specif
toward
hbv
modifi
fulli
function
cell
reinfus
chronic
infect
patient
technolog
engin
lymphocyt
abl
recogn
lyse
hbv
infect
hepatocyt
importantli
hbvspecif
tcr
reprogram
cell
capabl
caus
drop
hbsag
produc
hcc
cell
integr
hbvdna
hbsag
posit
patient
hepatocellular
carcinoma
hcc
also
abl
induc
reduct
pulmonari
metastas
anoth
case
hbvrelat
hcc
neg
hbv
antigen
express
analysi
immunohistochemistri
latter
studi
short
hbvdna
fragment
integr
hcc
cell
genom
sequenc
use
select
hbvspecif
tcr
individu
engin
cell
immunotherapi
hbvspecif
tcr
cell
hlaclass
restrict
therefor
recogn
viral
peptid
context
appropri
present
hla
molecul
import
advantag
approach
hbvspecif
tcrt
cell
recogn
circul
antigen
thu
inhibit
high
quantiti
solubl
antigen
typic
present
serum
chb
patient
moreov
cell
transient
express
hbvspecif
tcr
recent
gener
messeng
rna
mrna
electropor
technolog
adopt
transfer
hbv
infect
human
liver
chimer
mice
thank
short
life
span
strategi
engin
cell
adopt
transfer
escal
dose
thu
reduc
risk
potenti
liver
toxic
induc
progress
immunemedi
viremia
reduct
addit
safer
approach
avoid
risk
sever
liver
damag
research
construct
tcrreprogram
nonlyt
cell
abl
produc
low
amount
perforin
granzym
b
capabl
limit
viral
infect
activ
antivir
cytidin
deaminas
hbvinfect
hepatocyt
altern
strategi
cell
abl
recogn
hbvinfect
target
independ
patient
hla
haplotyp
engin
use
chimer
antigen
receptor
car
combin
hbvspecif
antibodi
fragment
costimulatori
molecul
zeta
intracellular
domain
chimer
receptor
retrovir
deliv
primari
human
cell
technolog
could
recogn
conform
nonprocess
antigen
cell
surfac
mhc
class
iindepend
manner
regard
car
cell
direct
hbsag
protein
scar
enabl
primari
human
cell
recogn
kill
hbv
infect
hepatocyt
express
hbsag
surfac
elimin
viral
cccdna
vitro
moreov
hbv
transgen
mous
model
cell
express
chimer
antigen
receptor
specif
hbv
envelop
protein
local
liver
adopt
transfer
abl
reduc
hbv
replic
howev
recent
studi
highlight
limit
immunocompet
transgen
mous
model
describ
human
scar
cell
reject
murin
immun
system
hurdl
recent
overcom
specif
induc
toler
humanderiv
car
domain
lead
persist
scar
cell
antivir
effect
differ
model
studi
hbsagcar
cell
recent
gener
persist
hbvinfect
chimer
immunodefici
mice
harbor
human
liver
viral
cccdna
infect
hepatocyt
hbvdna
hbsag
level
reduct
transfer
car
cell
report
also
anim
base
observ
adopt
transfer
redirect
cell
repres
potenti
immunemodulatori
approach
therapeut
reconstitut
antivir
protect
perspect
specif
concern
regard
risk
readminist
patient
engin
cell
may
undergo
function
inhibit
suppress
mechan
respons
cell
exhaust
endogen
antigenspecif
lymphocyt
inde
adopt
transfer
cell
report
display
suscept
inhibitori
coreceptormedi
exhaust
issu
address
cancer
model
associ
checkpoint
blockad
car
cell
therapi
engin
downmodul
checkpoint
inhibitor
express
cell
recent
studi
describ
shrna
knockdown
tcrredirect
cell
well
intrahepat
lymphocyt
chb
hcc
patient
lentivir
vector
transduct
engin
cell
demonstr
enhanc
function
cultur
also
microfluid
model
cultur
recreat
characterist
tumor
microenviron
high
express
howev
upon
repetit
antigen
stimul
knockdown
led
compensatori
increas
altern
coinhibitori
receptor
phenotyp
featur
apoptosi
senesc
thu
demonstr
engin
cell
therapi
still
need
refin
order
highli
effect
among
differ
approach
studi
improv
genet
modifi
cell
therapi
recent
report
highlight
import
modul
vitro
cart
cell
metabol
transfer
vivo
interestingli
given
grow
understand
metabol
dysregul
key
alter
exhaust
cell
improv
adopt
cellular
immunotherapi
metabol
precondit
cart
cell
current
address
set
malign
intervent
aim
promot
memori
celllik
metabol
oxid
phosphoryl
oxpho
reduc
aerob
glycolysi
attempt
optim
metabol
profil
immun
cell
vitro
adopt
transfer
although
grow
number
studi
current
address
engin
cell
therapi
challeng
potenti
present
clinic
manag
set
chronic
hbv
infect
remain
technic
complex
difficult
appli
larg
number
patient
restor
function
effici
adapt
respons
believ
possibl
strategi
control
hbv
infect
chronic
infect
patient
proof
principl
actual
achiev
vivo
still
lack
evid
differ
model
chronic
viru
infect
persist
elev
antigen
load
inhibit
b
cell
function
data
avail
chronic
hbv
infect
support
notion
declin
antigen
allow
b
cell
function
reconstitut
despit
inhibit
antigen
product
may
actual
repres
first
possibl
strategi
put
place
reconstitut
adapt
respons
consider
high
antigenemia
constantli
present
chronic
infect
patient
amplifi
effect
checkpoint
blockad
metabol
modul
propos
make
cell
respons
antigen
boost
vaccin
thu
sequenti
combin
administr
differ
compound
differ
complementari
effect
protect
immun
respons
may
necessari
counteract
number
inhibitori
mechan
known
simultan
oper
chronic
hbv
infect
may
repres
problem
vivo
applic
safeti
first
requir
novel
hbv
therapi
especi
consider
optim
toler
avail
treatment
addit
extent
dysfunct
b
cell
expos
decad
differ
inhibitori
mechan
correct
still
open
issu
insuffici
cell
function
reconstitut
may
repres
major
limit
cur
potenti
immun
modulatori
therapi
context
adopt
transfer
genet
engin
cell
produc
vitro
either
recogn
hlapeptid
complex
hla
restrict
manner
hbv
antigen
hla
independ
fashion
infect
liver
cell
allow
bypass
hurdl
repres
function
cell
reconstitut
treatment
howev
practic
difficult
appli
clinic
moreov
adopt
transfer
cell
may
undergo
suppress
effect
trigger
inflam
intrahepat
environ
contribut
inactiv
autolog
hbvspecif
cell
inhibit
interact
may
associ
safeti
problem
relat
size
cytotox
cell
infus
possibl
solut
may
silenc
key
intracellular
coinhibitori
pathway
reliev
intrahepat
suppress
amplif
noncytolyt
potenti
engin
cell
would
make
hbv
cure
effect
less
danger
infect
liver
thu
addit
work
need
find
suitabl
solut
limit
risk
improv
efficaci
simplifi
clinic
applic
adopt
transfer
intervent
one
hand
character
better
featur
cell
exhaust
perspect
identifi
optim
strategi
reconstitut
fulli
protect
antivir
b
cell
function
